A teal curved bead chain beside a blank research sheet.

Our evidence assessments are specific to an outcome, population, and formulation.

Read our grading method

SS-31 / elamipretide

Explore SS-31 / elamipretide study records from the local packet, with missing evidence clearly marked.

Research topics
Primary investigators

Recorded source check: 3 October 2026

Review and updates

Overview

SS-31 / elamipretide has research records linked below from the primary PDF collection. These records provide the source passages and study details needed for an assessment, but the collection has not yet been synthesized into an outcome-specific clinical review on this page. A paper’s design, population, formulation, and measured endpoints determine what it can support. The guide therefore distinguishes access to the research from established conclusions about benefits, safety, dosing, or combination use, leaving those questions open where assessment is incomplete.

Benefits

Research records for SS-31 / elamipretide are linked in the study collections below, but their presence is not itself an assessment of clinical benefit. A useful benefit claim needs an identifiable outcome, an appropriate comparison, and a description of who or what was studied. Laboratory activity, a biomarker response, and an improvement in symptoms should be assessed separately. Until the relevant results and limitations have been evaluated, this guide does not assign an effectiveness grade or translate a proposed use into an established benefit.

Safety

This SS-31 / elamipretide guide does not yet provide a complete clinical safety assessment for a specific formulation and use. Such an assessment would need the exposure, route, participant characteristics, adverse events, and duration of follow-up from the relevant primary studies. Missing safety information cannot be interpreted as an absence of risk, and a reported event needs context before causation is assigned. Findings from one setting should remain separate from claims about another product, population, or combination.

Contraindications

The evidence summarized on this SS-31 / elamipretide page is not sufficient to construct a complete contraindication list for clinical use. A study’s inclusion and exclusion criteria describe its selected participants, but they do not determine suitability for everyone outside that study. Interpreting a potential contraindication requires the exact product, intended use, health condition, and supporting evidence. This section therefore leaves unanswered suitability questions explicit instead of turning unstudied circumstances into either permission or a categorical clinical rule.

Interactions

This guide does not establish an interaction profile for SS-31 / elamipretide with other peptides, medicines, or supplements. To evaluate a particular combination, the relevant evidence would need to identify the coadministered substances, formulation, route, and measured effects. Results for ingredients studied separately cannot determine whether combining them changes benefit, exposure, or harm. Related stack pages distinguish those ingredient findings from direct combination evidence and keep any unresolved interaction questions visible.

Forms & dosing

A validated dosing recommendation for SS-31 / elamipretide cannot be inferred from the material currently summarized in this guide. When study records report an amount or concentration, that value belongs to the specific preparation, route, schedule, and experimental setting described in the source. Laboratory concentrations and human treatment regimens should remain separately identified. This page will not convert an isolated reported number into a consumer dose, a cycle, or a protocol for a different formulation or combination.

Results & stopping

This SS-31 / elamipretide guide does not establish a general time to benefit or what happens after treatment stops. Those questions require a defined outcome, repeated measurements, and follow-up that extends beyond the intervention when persistence is being assessed. A pharmacological response during exposure would answer a different question from a sustained improvement in symptoms or function. Any future timeline should therefore state exactly what changed, when it was measured, and whether the study actually observed participants after discontinuation.

Product quality

The studies attached to a topic do not, by themselves, validate the quality of a commercial SS-31 / elamipretide product. Evaluating a particular preparation requires information about its identity, composition, batch, and intended route, with testing appropriate to the claim being made. A supplier’s label cannot establish that the contents match a research intervention. This guide keeps product characterization separate from clinical effectiveness and does not endorse a vendor or finished product on the basis of an ingredient study.

Status

This page does not provide a verified, product-specific regulatory determination for SS-31 / elamipretide. Approval, research use, and availability need to be distinguished for the exact preparation, indication, and jurisdiction being considered. A publication establishes that an experiment was reported; it does not by itself establish authorization to market a product. Regulatory conclusions should be added only with a dated primary agency source, while research findings remain tied to the intervention actually investigated.

Evidence

These assessments describe confidence in a specific outcome for the population and formulation actually studied. Select an outcome or source count to inspect the supporting sources, methods, and limitations before applying a finding to a broader claim. Research on an individual ingredient is kept separate from evidence about a complete stack, and laboratory findings are distinguished from clinical outcomes. An unassessed question remains unresolved; it should not be read as evidence of either effectiveness or ineffectiveness. How we grade evidence.

Selected findings and their main limitations. Open an outcome or source count for the complete assessment. Counts refer to cited documents, not necessarily independent studies.
Outcome, finding and study designEvidence certaintySources

No outcome assessment is available for this guide yet. Source records below have not been synthesized into an assessment of benefit or safety.

Inspect the available research

Research Feed

Studies

Open a study to read its findings and limits, then explore the source passages and PDF details. Numbered citations link to References below.

PDF recordExpanded-access use of elamipretide in a patient with membrane protein-associated neurodegeneration
PDF recordExpanded-Access Use of Elamipretide Improves Quality of Life in Patients With Rare Mitochondrial Disorders Characterized by Ophthalmic Symptoms: A Case Series
PDF recordA randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy
PDF recordUse of Elamipretide in patients assigned treatment in the compassionate use program: Case series in pediatric patients with rare orphan diseases
PDF recordMitochondria dysfunction and increased expression of WNT5A and BNIP3 in tenocytes obtained from patients with tendinopathy
PDF recordA phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism
PDF recordExpanded-access use of elamipretide in a newborn with Barth syndrome: a case report
PDF recordTreatment with the mitochondrial-targeted antioxidant peptide SS-31 rescues neurovascular coupling responses and cerebrovascular endothelial function and improves cognition in aged mice
PDF recordROS-responsive chitosan-SS31 prodrug for AKI therapy via rapid distribution in the kidney and long-term retention in the renal tubule
PDF recordReduction of Ischemia/Reperfusion Injury With Bendavia, a Mitochondria-Targeting Cytoprotective Peptide
PDF recordElamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice
PDF recordNatural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome
PDF recordIdentifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data
PDF recordGenotype‑specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER‑3 trial
PDF recordInitial Psychometric Evaluation of the Barth Syndrome Symptom Assessment (BTHS‑SA) for Adolescents and Adults in a Phase 2 Clinical Study
PDF recordRandomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy
PDF recordEfficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy The MMPOWER-3 Randomized Clinical Trial
PDF recordIn vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial
PDF recordSS-31 Peptide Reverses the Mitochondrial Fragmentation Present in Fibroblasts From Patients With DCMA, a Mitochondrial Cardiomyopathy
PDF recordLate-life restoration of mitochondrial function reverses cardiac dysfunction in old mice

FAQs

What can this guide currently establish about SS-31 / elamipretide?
Quick answer:

Research records for SS-31 / elamipretide are linked in the study collections below, but their presence is not itself an assessment of clinical benefit. A useful benefit claim needs an identifiable outcome, an appropriate comparison, and a description of who or what was studied. Laboratory activity, a biomarker response, and an improvement in symptoms should be assessed separately. Until the relevant results and limitations have been evaluated, this guide does not assign an effectiveness grade or translate a proposed use into an established benefit.

Do reported study amounts establish a dosing recommendation?
Quick answer:

A validated dosing recommendation for SS-31 / elamipretide cannot be inferred from the material currently summarized in this guide. When study records report an amount or concentration, that value belongs to the specific preparation, route, schedule, and experimental setting described in the source. Laboratory concentrations and human treatment regimens should remain separately identified. This page will not convert an isolated reported number into a consumer dose, a cycle, or a protocol for a different formulation or combination.

Update History

Evidence and review status

Recorded source check
Subsequent substantive evidence update
No later update is recorded for SS-31 / elamipretide.
Independent clinical review
Pending; this selected-source guide is AI-assisted.

A source-check date is not an exhaustive literature-search cutoff or an independent approval. Adding a paper to the catalogue does not mean its findings have been incorporated into an outcome assessment.

Read the editorial method

References

0 sources

This page does not yet have an assessed reference supporting a clinical conclusion about the complete topic. Ingredient links and the broader source library can help locate relevant research, but a related paper is not automatically evidence for the intervention named here. Any future citation needs to be matched to its actual population, formulation, comparison, and outcome. The absence of a reference on this page describes the present review and should not be interpreted as a literature-wide absence of research.